Oils enriched with diacylglycerols and phytosterol esters for use in the reduction of blood cholestrol and triglycerides and oxidative stress

A technology of phytosterol esters and phytostanol esters, applied in edible oil/fat, application, food science, etc., can solve problems such as no proof or discussion

Inactive Publication Date: 2006-07-26
ENZYMOTEC
View PDF4 Cites 11 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although it is commented in this patent that a synergistic effect on lipid metabolism can be expected whe

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Oils enriched with diacylglycerols and phytosterol esters for use in the reduction of blood cholestrol and triglycerides and oxidative stress
  • Oils enriched with diacylglycerols and phytosterol esters for use in the reduction of blood cholestrol and triglycerides and oxidative stress
  • Oils enriched with diacylglycerols and phytosterol esters for use in the reduction of blood cholestrol and triglycerides and oxidative stress

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0107] 药物组合物的制备是本领域公知的,参见,例如,US专利5,736,519,5,733,877,5,554,378,5,439,688,5,418,219,5,354,900,5,298,246,5,164,372,4,900,549,4,755,383,4,639,435,4,457,917和4,064,236。 The combination used in the present invention can preferably be mixed with excipients, carriers and / or diluents, and any preservatives, etc. Pharmaceutically acceptable excipients are known in the art, see for example the above-mentioned US patents. Examples of excipients include dextrose, mannitol, inositol, sucrose, lactose, fructose, starch, corn starch, microcrystalline cellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, polyvinylpyrrolidone, and the like. Optionally, thickeners such as natural colloids, cellulose derivatives, acrylic polymers or vinyl polymers, etc. may be added.

[0108] The pharmaceutical composition is preferably presented as a liquid, solid or semi-solid. Liquid preparations are preferably presented as aqueous suspensions, oily suspensions or microencapsulated compositions. S...

Embodiment 1

[0150] Olive Oil, Olive Oil + Phytosterols and Olive Oil MultOil in E 0 Antioxidant effects against macrophage lipid peroxidation in mice

[0151] As mentioned above, oxidative stress is involved in the pathogenesis of atherosclerosis. Atherosclerosis is associated with plasma LDL and lipid peroxidation in arterial cells, including macrophages [Aviram M. (2000) Free. Radic. Res. 33:S85-97; Aviram M. and Fuhrman B. (1998) Mol. Cell. Biochem. 188:149-159]. Under oxidative stress, macrophage superoxide levels increase, and macrophages produce reactive oxygen species, leading to increased atherogenesis [Plump A.S. et al. (1992) Cell 71:343-353].

[0152] Apolipoprotein E deficiency (E 0 ) mice are widely used as animal models of atherosclerosis because they develop severe hyperlipidemia and atherosclerotic lesions when fed solid food (chow diet). In addition, E 0 Accelerated atherosclerosis in mice is associated with increased lipid peroxidation of plasma lipoproteins and art...

Embodiment 2

[0170] Atherosclerotic apolipoprotein E deficiency (E 0 ) Effects of MultOil-c and MultOil-f on lipoprotein and macrophage atherosclerosis and on atherosclerosis development in a mouse model. Deficiency of apolipoprotein E (apoE 0 ) mice were 8 weeks old. Randomly assigned to the groups described below (5 mice per group). Mice received regular solid chow and, in addition, were fed (by gavage) once every three days as follows:

[0171] Group I :

[0172] 1. Placebo group: did not receive any additional oil.

[0173] 2. Canola oil group (control): fed with 60 μl of canola oil.

[0174] 3. MultOil-c group: fed with 60 μl MultOil-c.

[0175] Group II :

[0176] 1. Placebo group: did not receive any additional oil.

[0177] 2. MultOil-f group: fed with 60 μl MultOil-f.

[0178] Each mouse consumes approximately 5 mL of water / day, and 5 g of solid food / day

[0179] Oil preparations for feeding

[0180] The amount of MultOil-c and MultOil-f fed to mice was based on t...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention relates to the use of a composition comprising a combination of diacylglycerol(s) (DAG), mainly 1,3-diacylglycerol(s), and phytosterol and/or phytostanol ester(s) (PSE) dissolved or dispersed in edible oil and/or edible fat, in the manufacture of nutritional supplements and orally administrable pharmaceutical preparations which are capable of reducing blood levels of both cholesterol and triglycerides and/or for lowering serum, serum LDL and macrophage oxidation levels, inhibiting the formation of foam cells and/or preventing the deleterious effects generated by lipid-induced oxidative stress. In addition, the composition of the invention, as well as the pharmaceutical preparations thereof, is suitable for the treatment and prevention of conditions related to atherosclerosis, such as cardiovascular disease (CVD), coronary heart disease (CHD) and diabetes mellitus.

Description

field of invention [0001] The present invention relates to the use of a composition comprising diacylglycerol (DAG), mainly 1,3-di Acylglycerols, and phytosterol esters and / or phytostanol (phytostanol) esters (PSE), the nutritional supplements and oral pharmaceutical preparations can reduce serum levels of both cholesterol and triglycerides, and also exhibit LDL- Antioxidant properties, and it is suitable for the treatment and prevention of cardiovascular disease (CVD) and coronary heart disease (CHD). Background of the invention [0002] All publications mentioned throughout this application are hereby incorporated by reference in their entirety, including all references cited therein. [0003] Coronary artery disease (eg, atherosclerosis) is a major cause of morbidity and mortality in the West, and its pathogenesis involves complex interactions between arterial wall cells, blood cells, and plasma lipoproteins [Rose R. (1993) Nature 362: 801-809; Glass C.K. and Witztum J....

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A23L1/30A61K31/20A61K31/575A61K31/56A23D9/013A61P9/00A23L
Inventor D·普拉特D·佩尔勒德A·舒尔曼
Owner ENZYMOTEC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap